

AVENIO ctDNA and Tumor Tissue Surveillance Panel



This 197-gene panel, which comes with the AVENIO ctDNA Surveillance Kit and the AVENIO Tumor Tissue Surveillance Kit, is specially designed and optimized for monitoring of tumor burden in lung cancer and colorectal cancer. Included in this panel are 17 biomarkers associated with various cancer types in the U.S. National Comprehensive Cancer Network (NCCN) and other guidelines.*

Gene	All Coding Regions	CRC	Lung	Breast	Gastric	Glioma	Melanoma	Ovarian	Thyroid	Pancreatic	Other Cancers	SNV	Indel [†]	Fusion [§]	CNV [§]
ALK			●								ALCL, Large B-Cell Lymphoma, Neuroblastoma, Inflammatory Myofibroblastic Tumor, Spitzoid Tumor, Rhabdomyosarcoma	●	●	●	
APC		●			●	●				●	HCC, Medulloblastoma, Desmoid	●	●		
BRAF		●	●			●	●	●	●		Borderline Ovarian, Cholangiocarcinoma, Spitzoid Tumor, Pancreas Acinar Carcinoma, Melanocytic Nevus, GIST	●	●		
BRCA1	●			●				●		●		●			
BRCA2	●			●		●		●		●		●			
DPYD**		●										●			
EGFR	●		●			●						●	●		●
ERBB2	●	● [†]	●	●	●	●		●				●	●		●
KIT							●				AML, Testicular Germ Cell Tumors, GIST, Thymic Carcinoma	●	●		
KRAS	●	●	●		●			●	●	●	AML, Juvenile Myelomonocytic Leukemia	●			
MET	●		●								Head and Neck Squamous Cell, HCC, Papillary RCC	●	●		●
NRAS		●	●				●		●		MM, AML, Juvenile Myelomonocytic Leukemia	●			
PDGFRA											GIST, Hypereosinophilic Syndrome	●			
RET		●	●						●		Pheochromocytoma, Spitzoid Tumor, Mucosal Neuroma	●		●	
ROS1			●		●	●					Spitzoid Tumor, Cholangiocarcinoma, Borderline Ovarian	●		●	
TP53	●	●	●	●	●	●		●		●	Various Leukemias, Adenocortical, Basal Cell Carcinoma, Esophageal, Soft Tissue and Bone Sarcomas, Head and Neck SCC	●	● ^{§§}		
UGT1A1 ^{††}		●										●			

All coding regions are based on the longest transcript from Ensembl build 82.

* National Comprehensive Cancer Network. <http://www.nccn.org>. October 15, 2016.

**Inactivating mutations are associated with sensitivity to fluoropyrimidines.

[†]Kavuri et al. Cancer Discovery 8: 832-41 (2015). PMID: 26243863.

^{††}Certain variants are associated with sensitivity to irinotecan.

[‡] Indels are limited to variants in a pre-specified list of positions, referred to as "Loci of Interest", except for EGFR exon 19 long deletions, EGFR exon 20 long insertions and MET long insertions, which are not restricted to a pre-defined set of Indels.

[§] Detection of Fusions and CNVs are limited to variants in a pre-specified list of positions, referred to as "Loci of Interest" in the AVENIO analysis software.

^{§§} Indel for TP53 is called for tissue only, not plasma.

AVENIO ctDNA and Tumor Tissue Surveillance Panel



Additional genes in the Surveillance Panel:

ABCC5	CDKN2A	DOCK3	GPR139	INSL3	MAP2	PAX6	SLC8A1	UGT3A2
ABCG2	CHRM2	DSC3	GRIA2	ITGA10	MAP7D3	PCDH15	SLITRK1	USH2A
ACTN2	CNTN5	DSCAM	GRIK3	ITSN1	MKRN3	PDYN	SLITRK4	USP29
ADAMTS12	CNTNAP2	EDSCAM	GRIN2B	KCNA5	MMP16	PDZRN3	SLITRK5	VPS13B
ADAMTS16	CPXCR1	EGFLAM	GRIN3B	KCNB2	MTX1	PGK2	SLPI	WBSCR17
ARFGEF1	CPZ	EPHA5	GRM1	KCNC2	MYH7	PHACTR1	SMAD4	WIPF1
ASTN1	CRMP1	EPHA6	GRM5	KCNJ3	MYT1L	PIK3CA	SOX9	WSCD2
ASTN2	CSMD1	EYS	GRM8	KCTD8	NAV3	PIK3CG	SPTA1	ZC3H12A
AVPR1A	CSMD3	FAM135B	GSX1	KEAP1	NEUROD4	PKHD1L1	ST6GALNAC3	ZFPM2
BCHE	CTNNB1	FAM151A	HACD1	KIAA1211	NFE2L2	POLE	STK11	ZIC1
BPIFB4	CTNND2	FAM71B	HCN1	KIF17	NLGN4X	POM121L12	SV2A	ZIC4
BRINP2	CYBB	FAT1	HCRT2	KIF19	NLRP3	PREX1	T	ZNF521
BRINP3	DCAF12L1	FBN2	HEBP1	KLHL31	NMUR1	RALYL	THSD7A	ZSCAN1
C6	DCAF12L2	FBXL7	HECW1	KPRP	NOL4	RFX5	TIAM1	
C6ORF118	DCAF4L2	FBXW7	HS3ST4	LPPR4	NPAP1	RIN3	TMEM200A	
CA10	DCLK1	FCRL5	HS3ST5	LRFN5	NR0B1	RNASE3	TNFRSF21	
CACNA1E	DCSTAMP	FOXG1	HTR1A	LRP1B	NRXN1	ROBO2	TNN	
CDH12	DDI1	FRYL	HTR1E	LRRC7	NXPH4	SEMA5B	TNR	
CDH18	DLGAP2	GBA3	HTR2C	LRRTM1	NYAP2	SLC18A3	TRHDE	
CDH8	DMD	GBP7	IFI16	LRRTM4	OPRD1	SLC39A12	TRIM58	
CDH9	DNTTIP1	GJA8	IL7R	LTBP4	P2RY10	SLC6A5	TRPS1	



Associations of variations or mutations in these genes with the listed diseases were sourced from the following: COSMIC, GeneCards, My Cancer Genome. Analysis performed 11/2016.

台灣羅氏醫療診斷設備股份有限公司
104台北市中山區民權東路三段2號10樓
(02) 2183 6688
MC-TW-01070
僅供研究用，不可用於臨床診斷